ASCCP Releases Innovative ‘Enduring Guidelines’ to Combat Cervical Cancer

CLARKSBURG, MD / ACCESSWIRE / March 7, 2024 / The American Society for Colposcopy and Cervical Pathology (ASCCP) is proud to announce a major milestone by the groundbreaking Enduring Guidelines initiative, aimed at revolutionizing the fight against cervical cancer.

In a bid to ensure the most current and effective clinical management strategies, the Enduring Guidelines process seeks to integrate emerging technologies and the latest scientific evidence into the management of this preventable disease. Cervical cancer, which is preventable through vaccination against human papillomavirus, screening and clinical management of abnormal results, remains a significant global health challenge. To address this, ASCCP, the American Cancer Society (ACS), the National Cancer Institute (NCI) and several other organizations initiated the Enduring Guidelines project following the establishment of the 2019 ASCCP Consensus Guidelines for Clinical Management – the first risk-based guidelines for cervical cancer.

The Enduring Guidelines effort ensures timely updates to the guidelines, incorporating rapidly emerging technologies and new scientific evidence. Two key papers mark significant milestones in this ongoing effort:

  • Nicolas Wentzensen, MD, PhD, MS, Division of Cancer Epidemiology and Genetics, National Cancer Institute: Outlines the Enduring Guidelines approach and methods, demonstrating a commitment to staying at the forefront of cervical cancer prevention and management.
  • Megan A. Clarke, PhD, MHS, Clinical Genetics Branch, Division of Cancer Epidemiology & Genetics, National Cancer Institute: Presents the first clinical recommendations from the Enduring Guidelines group on the use of dual stain cytology to manage abnormal cervical screening results. These recommendations offer invaluable insights into enhancing patient care and outcomes.

“The Enduring Guidelines initiative marks a significant step forward in our ongoing battle against cervical cancer,” says President of ASCCP, Dr. Levi S. Downs, Jr. MD, MS. “By continuously updating our clinical management strategies based on the latest evidence and technologies, we are better equipped to save lives and reduce the burden of this disease.”

ASCCP encourages healthcare professionals, researchers, and stakeholders to explore the Enduring Guidelines and join the collective effort to eradicate cervical cancer. For more information about the initiative and to access the latest clinical recommendations, visit ASCCP’s Enduring Guidelines page.

Furthermore, ASCCP invites individuals to explore the esteemed lineup of speakers at the 2024 ASCCP Scientific Meeting being held in New Orleans, May 2-4, which includes a session on “Enduring Guidelines: What’s Next” with Dr. Wentzensen. To view the speakers and their contributions, visit ASCCP’s 2024 Speakers page.

The American Society for Colposcopy and Cervical Pathology (ASCCP) is dedicated to improving the health of women through the delivery of high-quality, evidence-based care. ASCCP is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. For media inquiries or interviews, please contact: info@asccp.org

Contact Information
Robert Pulley
Membership Manager
info@asccp.org
301.857.7877

SOURCE: The American Society for Colposcopy and Cervical Pathology

View the original press release on newswire.com.

Staff

Recent Posts

DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Ascension Health Customers Whose Data May Have Been Compromised

NEWTOWN, Pa., Dec. 22, 2024 /PRNewswire/ -- The law firm of Edelson Lechtzin LLP is…

43 minutes ago

Daily Fit Notes Rolls Out Affordable Fitness Solutions for the Modern Lifestyle

Daily Fit Notes, founded by Justin Brey in New York, launches a text-based subscription fitness…

1 day ago

WillowWood Rebrand by DD.NYC Wins Gold Anthem Award for Product and Innovation in 2024 Rebrand

MT. STERLING, Ohio, Dec. 20, 2024 /PRNewswire/ -- WillowWood, a global leader in prosthetic solutions,…

2 days ago

Quantum Biopharma Announces Closing of Second Tranche

TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"…

2 days ago

Glow Lifetech Announces Completion of Final Payment under Swiss Pharma Share Exchange Agreement and Debt Settlement

Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink:…

2 days ago